Aethlon Receives Government and Industry Support for HIV and Hepatitis-C Trials in India

SAN DIEGO–(BUSINESS WIRE)–March 28, 2005–Aethlon Medical, Inc. (OTCBB:AEMD) announced today that it has been advised by Qualtran LLC, a contract research organization (CRO) managing clinical trials for Aethlon in India, that both the Government of India and Industry are supportive of Aethlon’s upcoming HIV and Hepatitis-C trials.

Mr. Sandeep Malik, President of Qualtran, stated, “We are pleased to disclose that Aethlon has received letters of support from both the Government of India and the Confederation of Indian Industry (CII), which is India’s premier business association.” Mr. Malik continued, “Members of Parliament, Ashok Argal and Shripad Naik are personally supportive of Aethlon’s HIV trials in India. They believe that if successful, Aethlon’s technology could have a profound impact on the condition of HIV patients in India and around the world.”

Mr. Malik concluded, “HIV infections in India could increase sharply if effective treatment strategies are not widely implemented. This could have devastating effects on the country’s economic and social systems. Aethlon’s Hemopurifier(TM) technology and forthcoming trials have been very well received by key opinion leaders in India.” According to the Gates Foundation, 5.1 million individuals in India were infected with HIV in 2004, a ten-fold increase over the last decade. It is projected that the number of HIV-infected citizens in India could increase to 20-25 million by 2010. Aethlon stated that site selection for the trials is under way, and that patient enrollment should begin in the coming months.